Key facts
- This page summarizes Tony W. Ho's Form 4 filing for CRISPR Therapeutics AG (CRSP).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 07 Dec 2021, 19:00.
Tony W. Ho - 03 Dec 2021 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)
- Reporting relationship
- Executive VP, Head of R&D
- Issuer ticker
- CRSP
- Reported as of
- 03 Dec 2021
- Net transaction value
- -$872,026
- SEC form
- 4
- Accepted by SEC
- 07 Dec 2021, 19:00:19 UTC
- Prior SEC filing
- 18 Oct 2021
- Next SEC filing
- 10 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Esposito, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Tony W. Ho filed Form 4 for CRISPR Therapeutics AG (CRSP) on 07 Dec 2021.
Change
- Previous filing in this sequence was filed on 18 Oct 2021.
- Current net transaction value: -$872,026.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRSP
transaction
Common Shares
Options Exercise
- Transaction value
- Shares
- +26,667
- Change %
- +70%
- Price
- Shares after
- 64,971
- Date
- 03 Dec 2021
- Ownership
- Direct
- Footnotes
- F1, F2
CRSP
transaction
Common Shares
Tax liability
- Transaction value
- $872,026
- Shares
- -12,607
- Change %
- -19%
- Price
- $69.17
- Shares after
- 52,364
- Date
- 06 Dec 2021
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRSP
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- +26,667
- Change %
- Price
- Shares after
- 13,333
- Date
- 03 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 26,667
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
Footnote F3
On December 3, 2019, the reporting person was granted 40,000 restricted stock units. On December 3, 2021, 26,667 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.